Real-World watch: is zavicefta safe for tough infections?

NCT ID NCT05733104

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study observes 600 patients in Korea who receive Zavicefta for complicated abdominal or urinary tract infections or hospital-acquired pneumonia. Researchers track side effects and how well the drug works. It is required by Korean regulators to ensure the drug's safety after market release.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zavicefta (ceftazidime-avibactam)
What this could lead to: If successful, this study will confirm that Zavicefta is safe and works well for serious infections in real-world use in Korea.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only monitors routine use, so no new treatment is being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AEROBIC GRAM-NEGATIVE ORGANISM INFECTION WITH LIMITED TREATMENT OPTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial urinary tract infection gram-negative bacterial infections Healthcare-Associated Pneumonia infectious peritonitis nosocomial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMPLICATED INTRA-ABDOMINAL INFECTION COMPLICATED URINARY TRACT INFECTION HOSPITAL-ACQUIRED PNEUMONIA

Real-World watch: is zavicefta safe for tough infections?

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions